398 related articles for article (PubMed ID: 33293516)
1. Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages.
Song M; Yeku OO; Rafiq S; Purdon T; Dong X; Zhu L; Zhang T; Wang H; Yu Z; Mai J; Shen H; Nixon B; Li M; Brentjens RJ; Ma X
Nat Commun; 2020 Dec; 11(1):6298. PubMed ID: 33293516
[TBL] [Abstract][Full Text] [Related]
2. SJI 2020 special issue: A catalogue of Ovarian Cancer targets for CAR therapy.
Benard E; Casey NP; Inderberg EM; Wälchli S
Scand J Immunol; 2020 Oct; 92(4):e12917. PubMed ID: 32557659
[TBL] [Abstract][Full Text] [Related]
3. Host Wnt5a Potentiates Microenvironmental Regulation of Ovarian Cancer Metastasis.
Asem M; Young AM; Oyama C; Claure De La Zerda A; Liu Y; Yang J; Hilliard TS; Johnson J; Harper EI; Guldner I; Zhang S; Page-Mayberry T; Kaliney WJ; Stack MS
Cancer Res; 2020 Mar; 80(5):1156-1170. PubMed ID: 31932454
[TBL] [Abstract][Full Text] [Related]
4. Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment.
Tanizaki Y; Kobayashi A; Toujima S; Shiro M; Mizoguchi M; Mabuchi Y; Yagi S; Minami S; Takikawa O; Ino K
Cancer Sci; 2014 Aug; 105(8):966-73. PubMed ID: 24826982
[TBL] [Abstract][Full Text] [Related]
5. Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment.
Terlikowska KM; Dobrzycka B; Terlikowski SJ
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800608
[TBL] [Abstract][Full Text] [Related]
6. ITLN1 modulates invasive potential and metabolic reprogramming of ovarian cancer cells in omental microenvironment.
Au-Yeung CL; Yeung TL; Achreja A; Zhao H; Yip KP; Kwan SY; Onstad M; Sheng J; Zhu Y; Baluya DL; Co NN; Rynne-Vidal A; Schmandt R; Anderson ML; Lu KH; Wong STC; Nagrath D; Mok SC
Nat Commun; 2020 Jul; 11(1):3546. PubMed ID: 32669559
[TBL] [Abstract][Full Text] [Related]
7. E3 Ubiquitin Ligase UBR5 Drives the Growth and Metastasis of Triple-Negative Breast Cancer.
Liao L; Song M; Li X; Tang L; Zhang T; Zhang L; Pan Y; Chouchane L; Ma X
Cancer Res; 2017 Apr; 77(8):2090-2101. PubMed ID: 28330927
[TBL] [Abstract][Full Text] [Related]
8. UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced
Wu B; Song M; Dong Q; Xiang G; Li J; Ma X; Wei F
Theranostics; 2022; 12(11):5086-5102. PubMed ID: 35836797
[No Abstract] [Full Text] [Related]
9. Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.
Khan AN; Kolomeyevskaya N; Singel KL; Grimm MJ; Moysich KB; Daudi S; Grzankowski KS; Lele S; Ylagan L; Webster GA; Abrams SI; Odunsi K; Segal BH
Oncotarget; 2015 May; 6(13):11310-26. PubMed ID: 25888637
[TBL] [Abstract][Full Text] [Related]
10. SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters.
Lyu T; Jiang Y; Jia N; Che X; Li Q; Yu Y; Hua K; Bast RC; Feng W
Int J Cancer; 2020 Mar; 146(6):1553-1567. PubMed ID: 31503345
[TBL] [Abstract][Full Text] [Related]
11. Targeting the immune microenvironment for ovarian cancer therapy.
Blanc-Durand F; Clemence Wei Xian L; Tan DSP
Front Immunol; 2023; 14():1328651. PubMed ID: 38164130
[TBL] [Abstract][Full Text] [Related]
12. Alternatively-Activated Macrophages Upregulate Mesothelial Expression of P-Selectin to Enhance Adhesion of Ovarian Cancer Cells.
Carroll MJ; Fogg KC; Patel HA; Krause HB; Mancha AS; Patankar MS; Weisman PS; Barroilhet L; Kreeger PK
Cancer Res; 2018 Jul; 78(13):3560-3573. PubMed ID: 29739756
[TBL] [Abstract][Full Text] [Related]
13. Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype.
Ko SY; Ladanyi A; Lengyel E; Naora H
Am J Pathol; 2014 Jan; 184(1):271-81. PubMed ID: 24332016
[TBL] [Abstract][Full Text] [Related]
14. Spheroid Formation and Peritoneal Metastasis in Ovarian Cancer: The Role of Stromal and Immune Components.
Rakina M; Kazakova A; Villert A; Kolomiets L; Larionova I
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682890
[TBL] [Abstract][Full Text] [Related]
15. Effective Targeting of TAG72
Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
Front Immunol; 2018; 9():2268. PubMed ID: 30510550
[TBL] [Abstract][Full Text] [Related]
16. SMAD specific E3 ubiquitin protein ligase 1 promotes ovarian cancer cell migration and invasion via the activation of the RhoA/ROCK signaling pathway.
Wang W; Du H; Liu H; Hu F; Liu G
Oncol Rep; 2019 Jan; 41(1):668-676. PubMed ID: 30542716
[TBL] [Abstract][Full Text] [Related]
17. β-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids.
Condello S; Morgan CA; Nagdas S; Cao L; Turek J; Hurley TD; Matei D
Oncogene; 2015 Apr; 34(18):2297-308. PubMed ID: 24954508
[TBL] [Abstract][Full Text] [Related]
18. Ovarian cancer stem cells and macrophages reciprocally interact through the WNT pathway to promote pro-tumoral and malignant phenotypes in 3D engineered microenvironments.
Raghavan S; Mehta P; Xie Y; Lei YL; Mehta G
J Immunother Cancer; 2019 Jul; 7(1):190. PubMed ID: 31324218
[TBL] [Abstract][Full Text] [Related]
19. CCL2 secreted from cancer-associated mesothelial cells promotes peritoneal metastasis of ovarian cancer cells through the P38-MAPK pathway.
Yasui H; Kajiyama H; Tamauchi S; Suzuki S; Peng Y; Yoshikawa N; Sugiyama M; Nakamura K; Kikkawa F
Clin Exp Metastasis; 2020 Feb; 37(1):145-158. PubMed ID: 31541326
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
Li T; Wang J
BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
